Revaprazan is a potassium-competitive acid blocker (P-CAB) primarily used in the treatment of gastric acid-related disorders. It reversibly and competitively inhibits the H⁺/K⁺-ATPase (proton pump), effectively reducing stomach acid production with rapid onset of action. This makes it beneficial for managing conditions such as gastroesophageal reflux disease (GERD), peptic ulcers (including those induced by long-term NSAID use), and gastritis. By decreasing acid secretion, it helps alleviate symptoms like heartburn, acid regurgitation, and stomach pain. Additionally, it aids in the healing of damaged esophageal, gastric, and duodenal lining caused by excessive acid exposure and reduces the risk of ulcer recurrence. Its targeted action and efficacy make it a valuable option in gastrointestinal therapy.